Table 1.
Patient and treatment characteristics
| Total patients | 83 |
| Female/male | 46 (55%)/37 (45%) |
| Median age/range | 67 years/28–94 years |
| Performance status 0–1/2–3 | 76/7 |
| Indication for radiation therapy | |
| Definitive therapy as an initial treatment | 65 (78%) |
| Postoperative salvage therapy for recurrent tumor | 11 (13%) |
| Postoperative adjuvant therapy for positive surgical margins | 7 (9%) |
| Tumor location | |
| Upper eyelid | 50 (60%) |
| Lower eyelid | 30 (36%) |
| Upper and lower eyelid | 3 (4%) |
| Maximum tumor size | |
| Median/range | 12 mm/4–35 mm |
| T stage (UICC 6th) | |
| T1 (≤5 mm) | 7 (9%) |
| T2 (5–10 mm) | 30 (36%) |
| T3 (>10 mm) | 38 (45%) |
| T4 (invades adjacent structures) | 8 (10%) |
| Radiation dose (EQD2 Gy) (α/β = 10) | |
| <60 Gy | 9 (11%) |
| 60 Gy | 64 (77%) |
| >60 Gy | 10 (12%) |
| Radiation modality, n(%) | |
| Electron | 77 (93%) |
| Photon | 6 (7%) |
| Bolus | 35 (42%) |
| Lead-based lens block | 68 (82%) |
EQD2 Gy = equivalent dose in 2 Gy.